ABSTRACT
Spiramycin was isolated by Pinnert-Sindico et al. (1955) from a strain of Streptomyces ambofaciens in France. It is a macrolide that has been used extensively in that country, but experience with it in the United Kingdom, North America, and Australia has been limited. It is now marketed in Europe (France, Germany, Italy, Spain), Canada, and Mexico. It is not commercially marketed in other jurisdictions but may be imported as required. In the United States, application to the Food and Drug Administration (FDA) is required for use. Trade names include Rovamycin (Sanofi/Aventis), Provamicina, Rovamycine, Rovamycine-250, Rovamycine-500, Rovamycina, Rovamicina, and Spiramycine Coquelusedal. Spiramycin is co-formulated with metronidazole in Europe under the trade name of Rodogyl.
